#South Korea #Seoul #CNS #ImmunoForge #LMT15

ImmunoForge's New LMT15 Platform Set to Transform CNS Drug Development

ImmunoForge Co., Ltd., a biopharmaceutical company in clinical stages focusing on rare and muscular diseases, has unveiled a groundbreaking platform called LMT15. This innovative technology aims to enhance drug delivery to the Central Nervous System (CNS) effectively overcoming the challenges posed by the Blood-Brain Barrier (BBB).

The LMT15 platform utilizes a specific mechanism known as Leptin receptor-Mediated Transcytosis (LMT). This pathway is not only revolutionary but also offers a significant competitive advantage over traditional methods of penetrating the BBB. The use of LMT allows for remarkably improved permeability into the brain while keeping side effects at bay, which is a critical aspect for CNS-targeted therapies.

A remarkable feature of the LMT15 platform is its integration with ImmunoForge's proprietary Elastin-Like Polypeptide (ELP) technology. This combination facilitates a unique, single-structure formulation that can penetrate efficiently into the BBB while also providing a long-acting once-a-month dosage. This dual functionality holds the promise of transforming the development of therapies targeting CNS disorders and long-term obesity treatments.

ImmunoForge's LMT15 technology has recently gained international recognition, earning first place at the prestigious Novo Nordisk Partnering Day 2026, an event co-hosted by prominent industry leaders like Novo Nordisk Pharma Korea and the Korea Health Industry Development Institute. After a vigorous review and pitching session, ImmunoForge stood out among numerous competitors in the biotech and healthcare fields. As a reward for their excellence, the company will receive expert mentoring and collaborative opportunities from Novo Nordisk and Novo Holdings, further validating their technological capabilities and positioning them favorably in the market.

Kiho Chang, Co-CEO of ImmunoForge, expressed, "Our LMT15 platform signifies a significant leap in tackling the complexities of brain drug delivery. Following our recognition from Novo Nordisk, we are eager to explore joint research and global technology transfers. We aim to collaborate with global partners to apply our ELP and LMT15 platforms to various candidates in CNS and metabolic diseases."

Earlier this year, the company filed a patent for the LMT15 platform and is now gearing up for full-scale development of its CNS pipeline. ImmunoForge continues to enhance its clinical-stage assets, including PF1801, which is currently in Phase 2 trials targeting Polymyositis and Dermatomyositis, and PF1804, developed for Duchenne Muscular Dystrophy cardiomyopathy, which has received FDA IND approval and Orphan Drug Designation.

ImmunoForge's commitment to innovation is evident as they explore ways to leverage their platforms to create impactful therapies. The company has thus far successfully raised around $32 million in investments, showcasing the strong confidence investors have in their potential.

With a burgeoning pipeline and strategic partnerships, ImmunoForge is dedicated to bringing transformative therapies to patients suffering from rare and muscular diseases globally. The unveiling of the LMT15 platform could represent a pivotal development in the quest for effective CNS drug therapies, offering hope and potential solutions for patients worldwide.